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INTRODUCTION 
 
1. The document at hand is the Feasibility Study for a Council of Europe Convention on Counterfeit 
Medicines/Pharmaceutical Crime
1
.  The first part of the feasibility study addresses the phenomenon of 
counterfeit medicines, the production and distribution of which should be qualified as pharmaceutical crime 
(Section 1). A number of initiatives and activities have taken place globally, regionally and nationally to tackle 
this phenomenon. The first part briefly touches upon the most significant and relevant ones (Section 2). The 
second part of the feasibility study then reflects on two issues: the need for an international legal instrument 
in tackling inter alia the phenomenon of counterfeit medicines (Section 1) and the potential of the Council of 
Europe in the drawing up of this instrument (Section 2). The third part is the core part and highlights 
relevant points that could be considered in a future legally binding instrument. As it concerns a criminal law 
treaty in the broad sense, the analysis of possible solutions to the problem and recommendations on the 
best solution to use – in short: the feasibility study – is geared towards:  
 
- Purpose and scope (Section 1); 
- Substantive criminal law (Section 2); 
- Prevention (Section 3); 
- Investigation, prosecution and procedural law (Section 4); 
- International cooperation (Section 5) and 
- Monitoring mechanism (Section 6) 
 
The objective of the feasibility study was to determine whether a legal instrument is likely, based on the 
evidence, to be both necessary and possible and that the outcomes will be capable of tackling the problem 
on a regional and national basis. The feasibility study will argue that there is an identifiable problem in 
counterfeit medicines and pharmaceutical crime in general; that it is a remediable problem; and that it can be 
remedied through legislation.   
 
PART I. THE PHENOMENON OF COUNTERFEIT MEDICINES/ PHARMACEUTICAL CRIME AND THE 
INITIATIVES AND ACTIVITIES TO TACKLE IT 
 
Section 1. The phenomenon of counterfeit medicines/pharmaceutical crime  
 
2. Counterfeiting is a common problem with several types of internationally traded goods. Counterfeit goods 
in Europe – whether manufactured here or brought in from other parts of the world – are on the rise, causing 
risks to consumers‟ health and well-being, distorting competition, damaging legitimate producers‟ interests 
and their brand names, undermining employment and reducing tax income
2
. All counterfeiting is to be 
deplored. For some goods such as designer clothing, the purchaser is usually aware that the product is not 
genuine. This is not the case for medicines where all purchasers are vulnerable and are likely to assume that 
the product is genuine and do not have the ability to decide otherwise. The patient is then at risk. All this 
makes that medicines cannot be regarded as mere commodities. The consequences of counterfeit 
medicines are particularly severe (death, disability and injury through a lack of or decreased therapeutic 
effect or inherent toxicity of the counterfeit) and the same goes for pharmaceutical crime in general.  
 
3. While statistics vary as to the level of counterfeit medicines on the global market, it has been claimed that 
counterfeit medicines affect 5% to 7% of the global pharmaceutical market
3
. Counterfeit medicines are 
present in all regions of the world, but developing countries bear the brunt of the problem. An estimated 25% 
of the medicines consumed in developing countries are believed to be counterfeit. In some countries (e.g. 
Nigeria) the figure is thought to be as high as 50%
4
. The European Union (EU) maintains that at least 3% of 
                                                 
1
 The important question as to whether the Council of Europe should draft a Convention on Counterfeit Medicines, or 
rather a Convention on Pharmaceutical Crime is analysed thoroughly in the first section of the core part of the feasibility 
study. See infra 18-21.  
2
 For a good report on the impact of counterfeiting of a wide number of products in Europe, see Centre d‟études 
internationales de la propriété industrielle (CEIPI), Impacts de la contrefaçon et de la piraterie en Europe, Rapport final, 
9 July 2004. URL:  
http://ec.europa.eu/justice_home/doc_centre/crime/studies/study_ceipi_counterfeiting_fr.pdf#search=%22%20Impacts%
20de%20la%20contrefa%C3%A7on%20et%20de%20la%20piraterie%20en%20Europe%22.  
3
 See Council of Europe, Partial Agreement in the Social and Public Health Field, Executive summary of the seminar 
“Counteract the counterfeiters! Limiting the risks of counterfeit medicines to public health in Europe by adequate means 
and measures”, 21-23 September 2005, Strasbourg (Appendix 1.1 Facts and Figures). 
4
 Although this is likely to reflect the definitions in place. 
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its pharmaceutical market is counterfeited
5
. The Council of Europe Counterfeit Medicines Survey Report
6
 
provides strong evidence that the counterfeit medicines problem is not insignificant in Western Europe and is 
not likely to go away in the foreseeable future. All European countries are affected whether as manufacturing 
sites, through transit, or markets.  
 
4. The counterfeit problem affects both human and veterinary medicines (patent-protected and non patent-
protected – generics), as well as medical devices (400,000 different medical devices on the European 
market). Mention can also be made of blood products, cells and tissues. The problem is present in both the 
legitimate and the illegitimate or black market.  
 
5. The current phenomenon of counterfeit medicines is due to a wide number of factors that can be 
summarised as follows
7
: regulatory gaps; incoordination between relevant authorities both nationally and 
internationally; regulatory body lack of resources; inefficient cooperation between stakeholders; weak 
administrative structures; weak enforcement and penal sanctions; weak export/transit regulations; disparity 
in the legal non-availability of certain types of high value medicinal products (unlicensed medicines) between 
countries; rapid rise in Internet pharmacy trade
8
; weak packaging and printing regulations; increasingly 
complex distribution chain with transactions involving many intermediaries
9
; high medicinal product prices; 
recent appearance on the market of so-called “life style and embarrassment” medicinal products; a move of 
organised crime into medicines counterfeiting associated with increasing sophistication in clandestine 
manufacture
10
; corruption and conflicts of interest.   
 
6. The increasingly complex distribution chain of transactions involving many intermediaries has to be 
acknowledged. The production and distribution of medicines is a complex activity consisting of several and 
rather articulated steps in both space and time. Criminals can infiltrate the legitimate production and 
distribution chain in different ways. Figure 1 taken from Hopkins, Kontnik and Turnage
11
 describes the 
different points of the production chain at which attacks might occur.  
 
Figure 1: Pharmaceutical production and counterfeit attack flowchart  
 
 
At distribution level a “business model of counterfeiting” has been put forward
12
. Figure 2 describes how 
wholesalers and local distributors can introduce counterfeit medicines into the legitimate system, dispensing 
them to official distributors such as public and private hospitals and clinics, and to individual patients. 
                                                 
5
 See footnote 3. 
6
 J. HARPER and B. GELLIE, Counterfeit medicines – Survey report, Council of Europe Publishing, 2006, 242 p. The 
report was commissioned by the Council of Europe Committee of Experts on pharmaceutical questions and its 
multisectorial Ad Hoc Committee on counterfeit medicines on the basis of an ongoing project to minimise public health 
risks posed by counterfeit medicines. It was based on the results of several surveys of Council of Europe Member States 
(Partial Agreement in the social and public health field) and European pharmaceutical sector stakeholders 
(manufacturers and wholesalers of medicinal products) conducted by the Ad Hoc Committee in 2003 and 2004 on the 
subject of legislative and administrative procedures applicable to counterfeit medicines. 
7
 Ibid. 
8
 See infra 7. 
9
 See infra 6. 
10
 See infra 8. 
11
 D. HOPKINS, L. KONTNIK and M. TURNAGE, Counterfeiting exposed, John Wiley & Sons Inc., 2003,   
12
 World Bank, HNP (Health, Nutrition and Population), Pharmaceuticals: Counterfeits, Substandard Drugs and Drug 
Diversion, March 2005, p. 2. URL: 
http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION/Resources/281627-
1109774792596/HNPBrief_2_9Mar05.pdf.  
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Figure 2: Business model of counterfeiting 
 
 
 
 
 
 
 
7. As regards the Internet pharmacy trade, it should be pointed out that the Internet as such is not the 
problem
13
. Nevertheless, it is an open window to distribution of counterfeit medicines
14
, a vehicle through 
which everything is promoted and subsequently supplied, often illegitimately. Criminals take advantage of 
the anonymity of the Internet and put the lives of an unsuspecting public at risk
15
.  
   
8. A major report produced by an independent consulting group has linked the phenomenon of counterfeit 
medicines to organised crime
16
. As for the involvement of organised criminal groups in the counterfeiting of 
medicines, it should be noted that the latter is a very lucrative business due to high demand and low 
production costs. The absence of deterrent legislation in many countries also encourages counterfeiters. In 
this sense the current phenomenon is a classic “high profit – low risk” story. In the EU Organised Crime 
Threat Assessment 2006 commodity counterfeiting is assessed as a rapidly expanding type of crime. It is 
stated that virtually all goods on sale are counterfeited, and that in addition to the significant economic loss, 
the serious threat posed to health and safety by inter alia counterfeit medicines must be considered
17
. Again 
proof of the fact that medicines cannot be regarded as mere commodities. 
 
9. In sum, it remains extremely difficult to properly map the phenomenon of counterfeit medicines – and 
pharmaceutical crime in general. This is largely due to its clandestine nature. Counterfeiters do not advertise 
their involvement and patients and healthcare professionals most likely will not know until after 
administration, if they know at all. The difficulties in measuring the scope of the phenomenon are also due to 
the absence of clear definitions of “counterfeit medicines” and “pharmaceutical crime”
18
. Not only does this 
absence reinforce the perception that medicines counterfeiting is no different from other types of 
counterfeiting (a fallacy in terms of public health consequences), it also leads to inconsistencies and non-
standardisation of reporting of counterfeit medicines. The absence of clear definitions is amplified by the lack 
of a European central reference point for collating the instances of counterfeit medicines. The consequence 
of this is that in Europe – as in the rest of the world – we still know too little (facts, figures and trends) of 
the phenomenon of counterfeit medicines – and pharmaceutical crime in general. The little we do 
know, however, justifies taking strong action.  
                                                 
13
 See also Council of Europe, Partial Agreement in the Social and Public Health Field, Selling and advertising of 
medicines on the internet, Prepared by the Committee of Experts on Pharmaceutical Questions, Strasbourg, 
13 November 2002. URL: http://www.coe.int/t/e/social_cohesion/soc-sp/Sale%20internet.pdf. This study aims to provide 
an overview on the state of e-commerce and electronic advertising of medicinal products in the member states of the 
Partial Agreement.  
14
 Not to mention adulterated and tampered medicines. See also infra 21. 
15
 Commission warns about fake drugs on the internet, IP/06/375, Brussels, 27 March 2006. 
16
 See G. SATCHWELL, A Sick Business. Counterfeit medicines and organised crime, The Stockholm Network, 2004. 
URL: http://www.efpia.org/2_indust/sickbusiness.pdf. 
17
 EUROPOL, EU Organised Crime Threat Assessment (OCTA) 2006, p. 9. 
18
 See infra 18-21. 
Local counterfeiter 
Importer of 
counterfeit 
drugs 
Middleman or 
Wholesaler 
Local 
distributors 
Private 
hospitals/clinics 
Public 
hospitals/clinics 
Individual 
patients 
CDPC-BU (2007) 01 - feasibility study – pharmaceutical crime 
- 6 - 
 
Section 2. Initiatives and activities to tackle the phenomenon of counterfeit medicines / 
pharmaceutical crime 
 
10. A number of initiatives and activities have taken place globally, regionally and nationally to tackle the 
phenomenon of counterfeit medicines and pharmaceutical crime in general – the latter however only to a 
smaller extent. The Pre-Report to the Feasibility Study on a Council of Europe Legal Instrument
19
 presents a 
global view thereof, with a particular focus on those initiatives and activities that impact on the European 
Region
20
.  Making reference to the listing of initiatives and activities in the Pre-Report facilitates the reflection 
on two issues in the second part of the feasibility study: 1) the need for a legal instrument in tackling the 
phenomenon of counterfeit medicines/pharmaceutical crime and 2) the potential of the Council of Europe in 
the drawing up of this instrument. The Pre-report has demonstrated that, overall, there are two very different, 
yet complementary ways to approach the phenomenon of counterfeit medicines – and pharmaceutical crime 
in general: 1) as a violation of intellectual property rights (IPR) and wider economic interests, and 2) as a 
public health problem.  
 
PART II. AN INTERNATIONAL LEGAL INSTRUMENT ON COUNTERFEIT MEDICINES / 
PHARMACEUTICAL CRIME 
 
Section 1. The need for an international legal instrument 
 
11. Despite all efforts that have been made to address the problem, an international legal framework 
covering counterfeit medicines is still lacking at present. Hence the clear need for an international legal 
instrument, the justifications of which are manifold
21
. 1) The potential threat to life and public health remains. 
Counterfeit medicines also undermine the confidence of patients and healthcare professionals in the 
healthcare system, not to mention the burden they impose on healthcare budgets. 2) Counterfeiting knows 
no boundaries or jurisdictions. Based on mounting evidence, national measures alone appear to be 
insufficient to address the international nature and scope of the phenomenon of counterfeit medicines. 3) At 
present Europe lacks a central reference point for collating all relevant data, as provided by the competent 
authorities and the pharmaceutical industry on the basis of clear definitions of “counterfeit medicines” and 
“pharmaceutical crime”. 4) Counterfeit medicines and pharmaceutical crime in general generate “high profit”, 
with only a “low risk” of apprehension. Moreover, several cases indicate links with organised crime. 
 
12. The need for a strong international instrument has already been acknowledged by the participants 
to the Seminar “Counteract the counterfeiters! Limiting the risks of counterfeit medicines to public health in 
Europe by adequate means and measures” (Strasbourg, 21-23 September 2005).  The issue whether this 
instrument should be a Council of Europe Convention was left aside. The Seminar Conclusions simply stated 
that “This instrument could be a Council of Europe Convention”
22
. At the International Conference “Europe 
against Counterfeit Medicines” (Moscow, 23-24 October 2006) the need for a strong international instrument 
was reiterated. The Moscow Declaration expresses the conviction of the participants that “an international 
legal instrument – Convention (…) – should be developed without delay under the aegis of the Council of 
Europe and adopted”
23
. The potential of the Council of Europe in the drawing up of this instrument is further 
reflected upon in the next section, considering both intrinsic and added value.   
                                                 
19
 Council of Europe, European Committee on Crime Problems (CDPC), Pre-Report to the Feasibility Study on a Council 
of Europe Legal Instrument (By Hugo K. Bonar, Scientific Expert), Strasbourg, 9 June 2006. 
20
 Some of the most significant and relevant ones discussed are: Council of Europe (CoE), European Union (EU), World 
Health Organisation (WHO), World Intellectual Property Organisation (WIPO), Organisation for Economic Cooperation 
and Development (OECD), European Patent Office (EPO) and the Permanent Forum on International Pharmaceutical 
Crime (PFIPC). 
21
 See Council of Europe, 55th Plenary Session of the CDPC, Strasbourg, 3-7 April 2006 – agenda item 7.4 
Counterfeiting (Notes on the presentation Mr. Johan Sabbe). See also Council of Europe, 51st session of the PC-OC, 
Strasbourg, 1-3 March 2006 – agenda item 6.3 Counterfeiting (Notes on the presentation Mr Hugo Bonar).   
22
 See footnote 3. 
23
 International Conference, Europe against Counterfeit Medicines, Moscow, Russian Federation, 23-24 October 2006, 
Moscow Declaration (§ 6).  
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Section 2. The potential of the Council of Europe 
 
13. The intrinsic values of the Council of Europe are inter alia the following. 1) Comprehensive 
membership: a Council of Europe Convention could cover (at least) 46 Member States, with fairly high 
standard of legal and healthcare systems, thus providing the opportunity to draft a high-quality text, both 
from the legal and the health point of view. 2) Rapidity: the Council of Europe is able to produce conventions 
in a relatively short time (e.g. 1 to 2 years). 3) Multidisciplinary approach: at the Council of Europe, the legal 
and the health sectors could usefully cooperate in the drawing up of the instrument. 4) Human – thus patient 
– rights based approach: a Council of Europe Convention would protect Article 2 (Right to life) of the 
European Convention on Human Rights
24
 by placing a positive obligation on each Party.  
 
14. As mentioned earlier, other international institutions are also active in the area of counterfeit medicines. 
However, their approach and/or working methods are different from those of the Council of Europe. The 
latter even has added value over global (WHO) and other regional (EU) initiatives. The WHO and the 
Council of Europe share the public health approach. Nevertheless, the WHO has abandoned the initial idea 
of having an international framework convention. Instead an International Medical Products Anti-
Counterfeiting Taskforce (IMPACT)
25
 was launched, as an immediate response to the need for urgent 
internationally coordinated action to combat counterfeit medicines. The European Commission approaches 
counterfeiting primarily as a violation of intellectual property rights. Medicines are covered by IPR 
legislation
26
, but not specifically targeted.   
 
15. A Council of Europe Convention could provide a ready-made basis for a WHO convention on a global 
scale. It could also provide the ready-made legislation for the EU in the field of public health. This is not to 
say that Council of Europe action is one-way traffic. On the contrary, a Council of Europe Convention would 
also benefit from drawing upon the WHO and EU acquis. 
 
PART III. POINTS TO CONSIDER IN A COUNCIL OF EUROPE CONVENTION ON COUNTERFEIT 
MEDICINES / PHARMACEUTICAL CRIME 
 
16. Judging from the second part of the feasibility study, there is indeed a need for a legal instrument. 
Moreover, the Council of Europe – with its European-wide legal and public health mandate based on the 
protection of human rights – can be seen as the most appropriate and best-equipped institution to draw up 
this instrument. This leaves the third part of this feasibility study with the question of the possible content of 
such an instrument. This part will highlight relevant points that could be considered in a future Council of 
Europe Convention on Counterfeit Medicines/Pharmaceutical Crime. As the future Council of Europe 
Convention concerns a criminal law treaty in the broad sense, the sections below cover: 1) Purpose and 
scope; 2) Substantive criminal law; 3) Prevention; 4) Investigation, prosecution and procedural law , 5) 
International cooperation and 6) Monitoring mechanism.   
 
Section 1.  Purpose and scope 
 
17. Ultimately, a Council of Europe Convention on Counterfeit Medicines/Pharmaceutical crime will be 
instrumental to protect the right to life (Article 2 European Convention on Human Rights) and the right to 
protection of health (Art. 11 revised European Social Charter
27
). This purpose statement could be in the 
very first Article of the future Convention, as well as in the Preamble to the Convention.  
 
18. As for the scope of the future Convention, overall, two approaches are possible: a minimalist approach 
leading to a Council of Europe Convention on Counterfeit Medicines and a maximalist approach ending in 
a Council of Europe Convention on Pharmaceutical Crime. Within each approach there is again more than 
one option. There is general agreement that counterfeiting of medicines comes under pharmaceutical crime, 
                                                 
24
 Convention for the Protection of Human Rights and Fundamental Freedoms, Rome, 4 November 1950, CETS – No 5. 
25
 IMPACT is a voluntary grouping of governments, organisations, institutions, agencies and associations from 
developing and developed countries working towards the common goal of fighting counterfeit medical products. Its 
establishment had been proposed by WHO and was endorsed by 160 participants at an international conference in 
Rome in February 2006. The Rome Conference issued a set of principles, calling for WHO to lead the establishment of 
IMPACT and set the conceptual framework for IMPACT‟s work.    
26
 The recent legislative steps adopted at EU level to increase the protection of intellectual property rights include: 
Regulation (EC) n° 1383/2003 on customs action, Directive 2004/48/EC on the enforcement of intellectual property rights 
and the July 2005 Proposals for a Directive and a Framework Decision on criminal measures.   
27
 European Social Charter (revised), Strasbourg, 3 May 1996, CETS – No 163. 
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which broadly speaking covers any criminal activity affecting pharmaceuticals. However, there appears to be 
less agreement about definitions of both “counterfeit medicines” and “pharmaceutical crime”.   
 
19. The WHO has developed following definition of counterfeit medicines: “they are deliberately and 
fraudulently mislabelled with respect to identity and/or source. Counterfeiting can apply to both branded and 
generic products and counterfeit medicines may include products with the correct ingredients but fake 
packaging, with the wrong ingredients, without active ingredients or with insufficient active ingredients”
28
. 
Despite the consensus this working definition represents, the definitions used in practice would differ enough 
to create problems
29
. Moreover, this definition – already dating from 1992 – has been perceived as too 
restrictive. Indeed, not only are medicines counterfeited, but also veterinary products, medical devices and 
other healthcare products. The future Council of Europe Convention could cater with modern developments 
in counterfeiting by covering healthcare products in general, i.e. medicines (both human and veterinary), 
medical devices and perhaps even cosmetics and nutrition supplements. Although the protection of public 
health would justify this sensu lato approach, it may not be achievable. The legal instrument also has to 
remain workable. It may, therefore, not be a recommended approach to include cosmetics and nutrition 
supplements insofar they fall outside the accepted definition of medicines
30
.   
 
20. Quid pharmaceutical crime in general? Although the term “pharmaceutical crime” has been in use since 
at least 1998 (establishment of the Permanent Forum on International Pharmaceutical Crime, PFIPC), there 
is no common understanding of its meaning and what it includes. Broadly speaking, pharmaceutical crime 
covers any criminal activity affecting pharmaceuticals
31
. The idea of inserting in the future Council of Europe 
Convention a definition of a term as cloudy as pharmaceutical crime should be approached with care.  An 
elegant alternative could be the simple enumeration, under the heading of pharmaceutical crime, of the 
separate criminal activities, excluding the mere irregularities. A parallel can be drawn with the Council of 
Europe Convention on Cybercrime
32
. Cybercrime – a crime area, not a crime as such – is left undefined. 
Instead, 9 criminal offences, grouped in 4 different categories, are listed. Counterfeiting would obviously be 
included. Adulteration and tampering of medicines and – again following a sensu lato approach – medical 
devices could be added to the list. The protection of public health is to benefit from this, as counterfeited, 
adulterated and tampered medicines create similar health risks. Within these limits
33
, a Council of Europe 
Convention on Pharmaceutical Crime (maximalist approach) would then be preferable to a legal instrument 
dealing merely with counterfeit medicines (minimalist approach).  
 
21. Tampering and adulteration involve the criminal manipulation of medicines and medical devices by an 
unauthorised party. These activities usually are carried out by subjects such as pharmacists, who may dilute 
packaged pharmaceuticals to increase profits, or other individuals who wish to hit innocent final consumers 
(patients)
34
.  Tampering is any unauthorised change of appearance of a product. Typical examples of 
tampering include any unauthorised breaking of seals, any change applied to the packing materials including 
the removal or addition of stickers, marks or other features. Adulteration is any unauthorised change of the 
quality of a product, including the addition of unauthorised or unlabelled substances.   
                                                 
28
 World Health Organisation, Counterfeit medicines, Fact sheet N° 275, Revised February 2006. URL: 
http://www.who.int/mediacentre/factsheets/fs275/en.  
29
 World Health Organisation, Health Technology and Pharmaceuticals, Combating Counterfeit Drugs: A Concept Paper 
for Effective International Cooperation, 27 January 2006 (original draft by Michelle Forzley, revised by WHO). URL: 
http://www.who.int/medicines/events/FINALBACKPAPER.pdf.  
30
 Cfr. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code 
relating to medicinal products for human use, OJ L 311, 28.11.2001, p. 67 (Directive as last amended by Directive 
2004/27/EC, OJ L 136, 30.4.2004, p. 34). Article 1 contains the definition of a “Medicinal product” for human use.   
31
 Examples of pharmaceutical crime: crimes involving narcotics and psychotropics, veterinary related problems, crimes 
involving borderline products and unlicensed medicines, doping (human and veterinary), counterfeiting and IPR related 
problems, gifts and inducements, forgery, publicity, theft, falsifying clinical trials, crime involving traditional Chinese 
medicines, Internet, diversion, licensing, import, export, transit – crimes, crimes involving mail order/courier, criminal 
violation of Good Manufacturing Practices (GMP), Good Distribution Practices (GDP), Good Clinical Practices (GCP), 
Good Veterinary Practices (GVP).  
32
 Convention on Cybercrime, Budapest, 23 November 2001, CETS – No 185. 
33
 Also outside the scope of what is being considered here are the areas of human health crimes, which are usually torts 
(civil law) and sometimes offences against persons (criminal law).  
34
 ABNH, Pharmaceutical counterfeiting, tampering and diversion. The threat to world health and the quest for solutions, 
December 2002, p. 1. URL: http://www.abnh.com/security/Pharm_whitePaper_WEBSITE.pdf.  
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Section 2. Substantive criminal law 
 
22. Harmonising substantive criminal law regarding counterfeiting/pharmaceutical crime will prevent 
criminals from “shopping” to find countries where they face no consequences for their behaviour.  
 
23. In both the minimalist approach (counterfeit medicines) and the maximalist approach (pharmaceutical 
crime) proper incriminations for counterfeit medicines – or healthcare products in the sensu lato option – 
need to be established. In the maximalist approach (pharmaceutical crime) incriminations also need to be 
established for adulteration and tampering of medicines and medical devices. Incriminations imply that each 
Party is to adopt such legislative and other measures as may be necessary to establish certain acts as 
criminal offences under national law.  
 
24. Specified criminal offences could include: manufacturing, storing, advertising
35
, offering for supply
36
, 
supplying
37
, importing, exporting and trafficking counterfeit medicines (material element or actus reus). The 
standard mental element or mens rea proposed for these offences is intent. However, in a given case it may 
be difficult to demonstrate that something was done intentionally. It is therefore worthwhile to consider 
negligence as well
38
, for all but the manufacturing of counterfeit medicines. To do so in the latter case would 
be a contradictio in terminis, deceit and the intention to deceive being essential to any counterfeit operation. 
The concept of negligence requires a violation of the required ordinary diligence often laid down in legal, 
administrative or technical rules, or rules generally acknowledged in the specific professions concerned.  
 
25. Both the counterfeit-part and the medicines-part of counterfeit medicines would then have to be defined 
taking into account what was said about the scope in Section 1
39
. The WHO definition could still serve as 
starting point. Inspiration can also be sought in definitions that have already been established around the 
world (e.g. Australia, Germany, Nigeria, Pakistan, Philippines, United States)
40
. The Australian counterfeit 
definition is interesting as it is the most elaborate of all. Under Australian law, therapeutic goods are 
counterfeit if the label or presentation of the goods; any document or record relating to the goods or their 
manufacture; any advertisement for the goods, contain a false representation of a following matter: the 
identity or name of the goods; the formulation, composition or design specification of the goods or of any 
ingredient or component of them; the presence or absence of any ingredient or component of the goods; the 
strength or size of the goods (other than the size of any pack in which the goods are contained); the strength 
or size of any ingredient or component of the goods; the sponsor, source, manufacturer or place of 
manufacture of the goods (Therapeutic Goods Act 1989 – SECT 42E)
41
. The German definition, which is 
provided by way of a prohibition, could also be built upon. Germany is in fact one of the very few European 
countries to have appropriate legislation and related experience. Under German law it is prohibited to 
produce or put into circulation pharmaceutical preparations that are considerably reduced in their quality due 
to deviation from recognised pharmaceutical standards, or are falsely labelled regarding identity or origin, or 
have a misleading or deceiving denomination, statement or design. A deception is present when: a 
therapeutic effectiveness or effects are attributed to a pharmaceutical preparation, which it does not have; 
the impression is incorrectly given that a success in another way may be expected with certainty or that no 
detrimental effects will arise following appropriate or long-term use of the pharmaceutical preparation; with 
the aim of deception about the pharmaceutical preparation‟s quality, denominations, statements or labels are 
used which are significant for the assessment of the pharmaceutical preparation (German Pharmaceutical 
Act, Arzneimittelgesetz (AMG) – Article 8).  
 
26. With regard to the adulteration and tampering of medicines and medical devices, criminal offences will 
also need to be formulated, rephrasing into substantive criminal law what was said in Section 1
42
.    
  
                                                 
35
 Including via the Internet. See also supra 7. 
36
 Id. 
37
 Id. 
38
 This is for example also the case in the Convention on the Protection of the Environment through Criminal Law, 
Strasbourg, 4 November 1998, CETS – No 172, Article 3 – Negligent offences.   
39
 See supra 18-21. 
40
 See J. HARPER and B. GELLIE, o.c, 16.2 (USA, Philippines); World Health Organisation, Health Technology and 
Pharmaceuticals, Combating Counterfeit Drugs: A Concept Paper for Effective International Cooperation, 27 January 
2006 (by Michelle Forzley), p. 12-13 (Nigeria, Pakistan, USA, Philippines) ; Concept Paper on the requirements of an 
international legal instrument or cooperation agreement on pharmaceutical crime, May 2006 (by Dietrich Schnädelbach), 
Annex 1 (USA, Germany, Nigeria, Australia).  
41
 URL: http://www.austlii.edu.au/au/legis/cth/consol_act/tga1989191/s42e.html.  
42
 See supra 21. 
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27.  The future Convention will need to make sure that attempting, aiding or abetting the commission of 
any of the offences established in accordance with the Convention are equally treated as criminal offences.  
  
28. Furthermore, the future Convention will need to ensure that legal persons can be held liable for any of 
these offences, committed for their benefit by any natural person.  Subject to the legal principles of the Party, 
the liability of a legal person may be criminal, civil or administrative and is without prejudice to the criminal 
liability of the natural persons who have committed the offence. Article 12 of the Convention on Cybercrime 
is a good example of such a “corporate liability” provision.   
 
29.  Apart from incriminations, the future Convention also needs to cover sanctions. Each Party should 
adopt such legislative and other measures as may be necessary to ensure that the criminal offences 
established in accordance with the Convention are punishable by “effective, proportionate and dissuasive” 
sanctions. Apart from deprivation of liberty (for natural persons) and fines and confiscation of objects, 
instruments and products stemming from offences or of goods whose value correspond to those products 
(for natural and legal persons) the Convention could also provide for following sanctions to be made 
available by each Party: destruction of the goods; total or partial closure, on a permanent or temporary basis, 
of the establishment used primarily to commit the offence; a permanent or temporary ban on engaging in 
commercial activities; placing under judicial supervision; judicial winding-up; a ban on access to public 
assistance or subsidies; publication of judicial decisions
43
. What “effective, proportionate and dissuasive” 
would then imply in terms of the level of sanctions is difficult to state at this point. There are hardly any 
precedents, as proper incriminations are currently lacking in most of the 46 Council of Europe Member 
States. The protection of public health should in any case function as the standard in establishing sentences 
and fines for the offences. In this respect following circumstance is to be regarded as aggravating: the result 
in significant damage to health. Committing the offences within the framework of a criminal organisation 
could also be regarded as an aggravating circumstance.  
 
Section 3. Prevention 
 
30. The future Convention will need to call upon Parties to take appropriate measures in the fields of 
research, information, raising the awareness of the public (patients and healthcare professionals) and the 
pharmaceutical industry, with a view to preventing counterfeit medicines/pharmaceutical crime and the 
negative effects on public health. The raising of public awareness is of paramount importance with regard to 
the dangerous practices associated with the Internet pharmacy trade
44
. In preventing medicines and medical 
devices from being counterfeited, adulterated or tampered, Parties to the future Convention could also be 
required to encourage the adoption of practical solutions involving new technologies which enable the 
authentication of medicines (techno-prevention). In the same preventive sense parties could be urged to 
move forward in the field of control of active ingredients, packaging material and manufacturing equipment.   
 
Section 4. Investigation, prosecution and procedural law  
 
31. Without proper enforcement, any effort to harmonise substantive criminal law
45
 is ineffectual. The 
investigation and prosecution of the criminal offences established in accordance with the future Convention 
will be for the Parties‟ police, customs and drug regulatory authorities, as well as for their judicial authorities. 
A Parties‟ obligation worth considering is the set-up of specialised units within the aforementioned 
authorities. A provision that could also be inserted is the obligation for Parties to provide legislation that gives 
adequate powers to each of the public authorities charged with enforcement. Ideally these enforcement 
powers (e.g. powers of entry, search and seizure under judicial warrant; judicial powers to order forfeiture 
and destruction of counterfeited, adulterated and tampered medicines and medical devices) would then have 
to undergo harmonisation as well. International cooperation is to benefit from this.  
 
32. Pharmaceutical crime is par excellence international crime, i.e. without boundaries or jurisdictions.  The 
future Convention therefore cannot do without  a provision on jurisdiction. Its purpose is twofold: 1) To 
ensure that Parties use their powers to prosecute and sentence offenders (at least) for offences committed 
wholly or partially on their territory; 2) To facilitate the settlement of conflicts of jurisdiction between Parties 
by requiring them to cooperate in deciding which of them will prosecute the alleged offender, when an 
                                                 
43
 Cfr. Article 4 Council Directive Proposal on criminal measures aimed at ensuring the enforcement of intellectual 
property rights. COMMISSION OF THE EUROPEAN COMMUNITIES, COM (2005)276 final, Brussels, 12 July 2005, 
Proposal for a European Parliament and Council Directive on criminal measures aimed at ensuring the enforcement of 
intellectual property rights. 
44
 See also supra 7. 
45
 See supra 22-29. 
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offence is within the jurisdiction of more than one Party. The provision on jurisdiction would then have to lay 
down a list of criteria to give some guidance. The traditional criteria of the European Convention on the 
Transfer of Proceedings
46
 could easily be complemented by more victim-related criteria (ordinary residence, 
nationality, origin victim; territory where the health damage occurred)
47
. Prosecutors must take into account 
the interests of victims (patients) and whether they would be prejudiced if any prosecution were to take place 
in one jurisdiction rather than another. Such consideration would include the possibility of victims claiming 
compensation. As part of their discussions to resolve these cases prosecutors should explore all the 
possibilities provided by current international conventions and instruments, for example to transfer 
proceedings and to centralise the prosecution in one Party. 
 
33. The aforementioned specialised units within Parties‟ police, customs, drug regulatory and judicial 
authorities
48
 could then be designated Single Points of Contact (SPOCs) within a pharmaceutical crime 
network, operating at both the national and the international level. This Network of Single Points of 
Contacts (SPOCs) is yet to be established and is to be given its legal basis in the future Convention. For the 
further implementation a complementary legal instrument under the aegis of the Council of Europe 
(preferably a Resolution) would be more appropriate. A model cooperation structure has already been 
developed and seems to be well-supported
49
. Although originally designed for counterfeit medicines, the 
scope could easily be extended to other forms of pharmaceutical crime. Figure 3 illustrates the model 
Network of Single Points of Contact (SPOCs)
50
.  
 
Figure 3: Network of Single Points of Contact (SPOCs) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34. In its national component the SPOC Network is to contribute to a better coordination and cooperation 
between the Parties‟ different sectorial authorities and between these authorities and the pharmaceutical 
sector stakeholders. The latter (manufacturers, wholesalers, distributors) would all have Responsible 
Persons (RPs), which are contacts at privates comparable to the contacts within the authorities. To allow the 
national SPOC Network to play its key-role in information, the future Convention will have to provide for 
                                                 
46
 See Article 8 in particular. European Convention on the Transfer of Proceedings in Criminal Matters, Strasbourg, 
15 May 1972, CETS – No. 073.  
47
 See T. VANDER BEKEN, G. VERMEULEN, S. STEVERLYNCK and S. THOMAES, Finding the best place for 
prosecution. European study on jurisdiction criteria, Antwerp-Apeldoorn, Maklu, 2002, 91 p.; T. VANDER BEKEN, G. 
VERMEULEN and O. LAGODNY, “Kriterien für die jeweils „beste‟ Strafgewalt in Europa. Zur Lösung von 
Strafgewaltskonflikten jenseits eines transnationalen Ne-bis-in-idem”, Neue Zeitschrift für Strafrecht, 2002, 624-628. See 
also COMMISSION OF THE EUROPEAN COMMUNITIES, COM (2005) 696 final, Brussels, 23 December 2005, Green 
Paper On Conflicts of Jurisdiction and the Principle of ne bis in idem in Criminal Proceedings (presented by the 
Commission). 
48
 See supra 31. 
49
 See Doc. P-SP-PH-CMED/RD6.1/8(2006), Guidance on the management of counterfeits – Cooperation structures and 
model procedure (Submitted by Dr. Tobias Gosdschan, January 2006). Cfr. International Conference “Europe against 
Counterfeit Medicines”, Moscow, 23-24 October 2006 
50
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mandatory reporting of instances of pharmaceutical crime. It should be noted, however, that the future 
Convention can only impose obligations on Parties – thus States. For the pharmaceutical industry to report, 
the Convention can merely oblige Parties to take all appropriate measures to at least encourage the industry 
to report to the competent national authorities.  For the competent authorities to report within and between 
themselves, the future Convention can only facilitate by making it an obligation to establish legislation to 
permit the exchange of information.    
 
Section 5. International cooperation  
 
35. In its international component the SPOC Network consists of the Parties‟ National SPOCs. It has been 
rightly recommended that the SPOCs of the drug regulatory authorities should also act as National SPOCs
51
. 
The future Convention would provide the International SPOC Network with a legal basis for the exchange 
of information. A legal basis for the routine passing of information within a multisectorial network is currently 
lacking. Each Party does have a mutual assistance programme and supporting legislation whereby evidence 
may be transferred through judicial routes
52
. Police and customs also have facilities within their own spheres. 
What does not exist, however, is one SPOC through which non-evidential information can be channelled on 
informal basis. The feeding of the National SPOCs will be crucial to the success of the International SPOC 
Network. As stated above, the future Convention can only facilitate by making it an obligation to establish 
legislation to permit the exchange of information. It should also be kept in mind that for police and judicial 
authorities, providing information where this would compromise ongoing investigations cannot be taken for 
granted. 
 
34. The SPOC Network is ideal to house a rapid alert system. Care is needed to distinguish between 
quality defect rapid alerts, of which there are many for non-criminal reasons and those necessary for 
highlighting and notifying pharmaceutical crime issues, notably counterfeit medicines. The Rapid Alert 
System (RAS) on quality defects of authorised medicines, currently used jointly by the Pharmaceutical 
Inspection Convention/ Pharmaceutical Cooperation Scheme (PIC/S) and by the European Medicines 
Agency (EMEA), could also be used for transmitting alerts on counterfeit medicines. Experience has shown 
that it is difficult to use the existing alert form. It was therefore proposed to complement the existing Rapid 
Alert System with a new form, set-up specifically for the exchange of information on counterfeit medicines
53
. 
Depending on further developments in this area, an amended RAS could be given a place in the future 
Convention. 
 
36. Qualifying as a criminal law treaty in the broad sense, the future Convention cannot but contain 
provisions on international cooperation in criminal matters
54
. In the context of the feasibility study it is 
sufficient to make reference to the Council of Europe acquis in this area – which is outstanding and in which 
drafters will be able to find inspiration. The future Convention should in any case impose a general obligation 
on the Parties to afford each other all possible co-operation within the limits of the (bi- and multilateral) 
agreements to which they have acceded and their national law. The reference made to instruments on 
cooperation can be formulated in a general way. It includes of course the Council of Europe Conventions on 
extradition
55
, mutual assistance in criminal matters
56
, the supervision of conditionally sentenced or 
conditionally released offenders
57
, the international validity of criminal judgements
58
, the transfer of 
proceedings in criminal matters
59
, the transfer of sentenced persons
60
, the laundering, search, seizure and 
confiscation of the proceeds of crime
61
.  
                                                 
51
 Ibid. 
52
 See also infra 36. 
53
 The Committee of Experts on Pharmaceutical Questions‟ ad hoc Group on Counterfeit Medicines developed such a 
new form in 2004, which was further optimised at the EU Medicines Enforcement Officer (EMEO). See 
http://www.coe.int/t/e/social_cohesion/soc-sp/public_health/pharma_and_medicine/Specific_projects.asp#TopOfPage. 
54
 Regardless of the fact that e.g. the 2005 Convention on Action against Trafficking Against Human Beings does not 
contain specific provisions. See Council of Europe Convention on Action against Trafficking Against Human Beings, 
Warsaw, 16 May 2005, CETS – No 197, Chapter VI – International co-operation and co-operation with civil society. 
55
 European Convention on Extradition, Paris, 13 December 1957, CETS – No 024. Additional Protocol, Strasbourg, 
15 October 1975, CETS – No 086. Second Additional Protocol, 17 March 1978, CETS – No 098. 
56
 European Convention on Mutual Assistance in Criminal Matters, Strasbourg, 20 March 1959, CETS – No 030. 
Additional Protocol, Strasbourg, 17 March 1978, CETS – No 099. Second Additional Protocol, Strasbourg, 8 November 
2001, CETS – No 182. 
57
 European Convention on the Supervision of Conditionally Sentenced or Conditionally Released Offenders, Strasbourg, 
30 November 1964, CETS – No 051. 
58
 European Convention on the International Validity of Criminal Judgements, The Hague, 28 May 1970, CETS – No 070. 
59
 European Convention on the Transfer of Proceedings in Criminal Matters, The Hague, 15 May 1972, CETS – No 073. 
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Section 6. Monitoring mechanism 
 
38. A final point to consider is the issue of the monitoring of the implementation of the future Council of 
Europe Convention. Providing for a monitoring mechanism in the Convention would prevent it from falling 
into disuse, or worse, from never being used at all. The Convention would clearly benefit from a monitoring 
mechanism à la GRECO (Group of States against corruption)
62
 or GRETA (Group of experts on action 
against trafficking in human beings)
63
. A yet to be established committee of experts (e.g. GREPHAC – Group 
of experts on Pharmaceutical Crime) could perform this delicate, yet indispensable task. The Council of 
Europe Secretariat could also play its role.  
                                                                                                                                                                  
60
 Convention on the Transfer of Sentenced Persons, Strasbourg, 21 March 1983, CETS – 112. Additional Protocol, 
Strasbourg, 18 December 1997, CETS – No 167.  
61
 Convention on Laundering, Search, Seizure and Confiscation of the Proceeds from Crime, Strasbourg, 8 November 
1990, CETS – No 141. 
62
 GRECO evaluates through a dynamic process of peer pressure, the compliance with undertakings contained in the 
legal instruments of the Council of Europe to fighting against corruption. See URL: 
http://www.coe.int/t/dg1/Greco/Default_en.asp.    
63
 See Council of Europe Convention on Action against Trafficking Against Human Beings, Warsaw, 16 May 2005, 
CETS – No 197, Chapter VII – Monitoring mechanism.    
